WO2000003033A1 - Utilisation de reactifs fluorescents pour identifier des lymphocytes cancereux ou actifs - Google Patents

Utilisation de reactifs fluorescents pour identifier des lymphocytes cancereux ou actifs Download PDF

Info

Publication number
WO2000003033A1
WO2000003033A1 PCT/US1999/015401 US9915401W WO0003033A1 WO 2000003033 A1 WO2000003033 A1 WO 2000003033A1 US 9915401 W US9915401 W US 9915401W WO 0003033 A1 WO0003033 A1 WO 0003033A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
esterase activity
cancerous
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015401
Other languages
English (en)
Other versions
WO2000003033A9 (fr
Inventor
James A. Thompson
Weidong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to AU52091/99A priority Critical patent/AU5209199A/en
Publication of WO2000003033A1 publication Critical patent/WO2000003033A1/fr
Publication of WO2000003033A9 publication Critical patent/WO2000003033A9/fr
Priority to US09/755,880 priority patent/US6696241B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Definitions

  • This invention relates to methods of identifying cancerous cells and activated lymphocytes using fluorescent reagents. More specifically, it relates to the use of fluorescent reagents to identify and quantify cancerous cells and activated T and B cells.
  • the fluorescence assay is used in conjunction with a test to measure ploidy or marker expression of the cells.
  • Neoplasia resulting in benign tumors can usually be completely cured by removing the mass surgically. If a tumor becomes malignant, as manifested by invasion of surrounding tissue, it becomes much more difficult to eradicate. Once a malignant tumor metastasizes, it is much less likely to be eradicated.
  • Early detection can help by allowing treatment in the early stages of the disease.
  • the three major cancers, in terms of morbidity and mortality, are colon, breast and lung. New surgical procedures offer an increased survival rate for colon cancer. Improved screening methods increase the detection of breast cancer, allowing earlier, less aggressive therapy. Numerous studies have shown that early detection increases survival and treatment options.
  • Melanoma is one of the human diseases for which there is an acute need of new therapeutic modalities. It is a particularly aggressive form of skin cancer, and occurs in increased frequency in individuals with regular unguarded sun exposure. In the early disease phases, melanoma is characterized by proliferation at the dermal-epidermal junction, which soon invades adjacent tissue and metastasizes widely. Once it has metastasized, it is often impossible to extirpate and is consequently fatal. Worldwide, 70,000 patients are diagnosed with melanoma and it is responsible for 25,000 reported deaths each year. The American Cancer Society projects that by the year 2000, 1 out of every 75 Americans will be diagnosed with melanoma. Neuroblastoma is a highly malignant tumor occurring during infancy and early childhood.
  • Small cell lung cancer is the most malignant and fastest growing form of lung cancer and accounts for 20-25% of new cases of lung cancer. Approximately 60,000 cases were diagnosed in the U.S. in 1996. The primary tumor is generally responsive to chemotherapy, but is followed by wide-spread metastasis. The median survival time at diagnosis is approximately 1 year, with a 5 year survival rate of 5-10%.
  • Breast cancer is one of the most common cancers and is the third leading cause of death from cancers in the United States, with an annual incidence of about 180,200 new cases among women in the United States during 1997. About 1,400 new cases of breast cancer were diagnosed in men in 1997. In industrialized countries, approximately one in eight women can expect to develop breast cancer. The overall mortality rate for breast cancer has remained unchanged since 1930. It has increased an average of 0.2% per year, but decreased in women under 65 years of age by an average of 0.3% per year. Preliminary data suggest that breast cancer mortality may be beginning to decrease, probably as a result of increased diagnoses of localized cancer and carcinoma in situ. See e.g., Marchant (1994) Contemporary Management of Breast Disease II: Breast Cancer, in: Obstetrics and
  • Non-Hodgkin's B cell lymphomas are cancers of the immune system that afflicted approximately 225,000 patients in the United States in 1996. These cancers are diverse with respect to prognosis and treatment, and are generally classified into one of three grades. The median survival of the lowest grade is 6.6 years and the higher grade cancers have much lower life expectancy. Virtually all non-Hodgkin's B cell lymphomas are incurable. New diagnoses of non-Hodgkins lymphomas have increased approximately 7% annually over the past decade, with approximately 53,000 new diagnoses in 1996. The increase is due in part to the increasing prevalence of lymphomas in the AIDS patient population.
  • Colon and rectal cancer accounted for an estimated 131,000 cases in 1997, including 94,000 of colon cancer and 37,000 of rectal cancer.
  • Colorectal cancers account for about 9% of new cancer diagnoses. About 55,000 deaths due to colorectal cancer occurred in 1997, accounting for about 10% of cancer deaths. Mortality rates for colorectal cancer have fallen 32% for women and 14% for men during the past 20 years, reflecting decreasing incidence rates and increasing survival rates. However, the mortality rate in African American men continues to rise. The 1 and 5 year relative survival rates for patients with colon and rectal cancer are 82% and 61%, respectively. When colorectal cancers are detected in an early, localized stage, the 5 year survival rate is 91%; however, only 37% of colorectal cancers are discovered at that stage. After the cancer has spread regionally to involve adjacent organs or lymph nodes, the rate drops to 63%. Survival rates for persons with distant metastases is 7%. Survival continues to decline beyond 5 years, and 50% survive 10 years.
  • Cervical cancer is a relatively common, potentially lethal disease. This cancer produces few symptoms, except for irregular bleeding (usually postcoital). Cervical dysplasia most often affects women in their 20's; carcinoma in situ affects women 30 to 39 years of age; and invasive carcinoma affects women older than 40 years old. Klemm et al.
  • Pap smears involve the manual histologic examination of stained cellular smears, the technology is laborious and fraught with variation in interpretation leading to the potential for false negative diagnoses. Davey (1997) Arch. Pathol. Lab. Med. 121 :267-9; Mitchell et al. (1995) Cytopath. 6:368-75. Other problems with the Pap smear test include severe cytotechnologist shortages, lack of internal quality controls, and problems with classification of results. Slagel et al. (1995) Diag. Cytopath. 13:26-30; and de Leon- Antoni (1991) Bol. Asoc. Med. P. R. 83:462-4.
  • cytologic findings is complicated by the fact that many different classification criteria are used for a single pathological condition.
  • inflammatory change or hormonal evaluation are not included in the system and classification is not compatible with evaluation of endometrial lesions or chorionic disease.
  • Pap smears may also be unreliable in detecting cervical intraepithelial neoplasia (CIN). Slawson et al. (1993) J Fam. Pract. 36:289-93.
  • An emerging area of cancer treatment is imrnunotherapy.
  • immunological strategies including: 1. Adoptive imrnunotherapy using stimulated autologous cells of various kinds; 2. Systemic transfer of allogeneic lymphocytes; 3. Vaccination at a distant site to generate a systemic tumor-specific immune response; and 4. Implantation of immune cells directly into the tumor.
  • Adoptive imrnunotherapy is directed towards providing the patient with a level of enhanced immunity by stimulating cells ex vivo (e.g., with a tumor-associated antigen or cytokine). and then re-administering them to the patient.
  • the cells are histocompatible with the subject, and are generally obtained from a previous autologous donation. Zarling et al. (1978) Nature 274:269-71; U.S. Patent No. 5.192,537; U.S. Patent No. 5,308,626;
  • the third imrnunotherapy strategy is the generation of an active systemic tumor- specific immune response of host origin. This is achieved by administering a vaccine composition at a site distant from the tumor.
  • Various types of vaccines have been proposed, including isolated tumor-antigen vaccines and anti-idiotype vaccines.
  • Another approach is to use tumor cells from the patient, or derivatives of such cells. Schirrmacher et al. (1995) J Cancer Res. Clin. Oncol. 121 :487-489; and U.S. Patent No. 5,484,596.
  • autologous or syngeneic tumor cells are genetically altered to produce a costimulatory molecule. Pardoll et al. (1992) Curr. Opin. Immunol. 4:619-23;
  • Tumor cells have been genetically altered to produce TNF-I , IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IFN-I , IFN-Kand GM-CSF.
  • the fourth imrnunotherapy strategy is intra-tumor implantation, which delivers effector cells directly to the tumor site.
  • CTL were generated in culture from an inbred rat strain allogeneic to the tumor cell line. The cells were found to lyse both tumor cells and Con A stimulated lymphoblasts of the same tissue type. The tumor-specific subset was deliberately selected and enriched as being specific for a determinant expressed only by the tumor.
  • the method can be conducted as follows: The tumor patient's leukocytes are co-cultured in a mixed lymphocyte cell reaction with healthy lymphocytes derived from an allogeneic donor.
  • the alloactivated cells are surgically implanted at the tumor site, and produce a mixture of cytokines which induce a primary immune response.
  • the host lymphoid cells identify both the graft lymphoid cells and tumor tissue as foreign.
  • lymphocytes may be activated in vitro by contacting them with a variety of known lectins, mitogens, antigens (e.g. alloantigens), antibodies, other cells (as in MLC), or any combination of these stimulants.
  • Cytotoxic T lymphocytes can be activated by, for example, immobilized anti-TcR monoclonal antibody, an immunocomplex of anti-TcR monoclonal antibody and immobilized rabbit anti-mouse antibody, a mixture of ⁇ -phorbol-12 myristate-13 acetate and ionophore A23187, and immobilized concanavalin A.
  • T cells can also be activated by superantigens (e.g. viral superantigens).
  • T cells A limited number of these kinases, Lck, Fyn, and Yes, are expressed in T cells. Of these, the best-characterized is the lymphocyte-specific tyrosine kinase, P56 sup lck (Lck), whose unique N-terminal domain interacts with the cytoplasmic tails of the CD4 and CD8 glycoproteins. These glycoproteins bind to surface MHC class II and class I molecules, respectively, and participate with the T cell antigen receptor (TCR) in early events of T cell activation. Rudd et al. (1988) Proc. Natl. Acad. Sci. USA 85:5190-5194;
  • lymphocyte activation markers include CD25, CD30, CD38, CD44, CD45 (including isoforms CD45RA and CD45RO), CDw49b (VLA-2), CD56, CD69, CD71 (transferrin receptor), CD72, 4F2, HLA-DR, IL-2R (Interleukin-2 receptor), IRac, LFA-1 (lymphocyte activation marker), and serum neopterin. Norazmi et al. (1995) Immunol. Cell. Biol. 73:245-248; Chiba et al. (1995) J Neurol. Sci. 132:170-173; Eskandari et al. (1997) Am. J.
  • Lymphoma 13:441-448 Yacyshyn et al. (1995) Int. J. Cancer 61 :47-474; and Kawamura et al. (1991) Cell Immunol. 133:468-83.
  • LFA-1 levels increase after cells are induced with bacterial lipopolysaccharides, and serum soluble IL-2 receptor levels are higher in rheumatoid patients than in controls.
  • Some of these markers have been studied for possible use in disease treatment.
  • CD30 for example, is a target for imrnunotherapy of Hodgkin's lymphoma. Schnell et al. (1995) Int. J. Cancer 63:238-44; and Barth et al. (1996) Ann. Oncol. 1 suppl. 4:135-141.
  • lymphocyte activation would be useful in examination of the potency of any given antigen, antibody, or lectin. Thus, the potential of the immune cell as a therapeutic can be assessed prior to therapy. These methods may also be used to determine if a certain drug is capable of blocking lymphocyte activation, as demonstrated in, for example, U.S. Patent No. 5,439,819.
  • Several methods have been devised for determining activation of lymphocytes. In the formazan reduction test, activated cells are treated with a tetrazolium compound, which the cell converts to formazan. The conversion is directly related to cell proliferation.
  • Typical tetrazolium compounds used are 2,3-bis (2-methoxy-4-nitro-5-sulfo-phenyl)-2H- tetrazolium-5-carboxanilide (XTT) or 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H- tetrazolium bromide (MTT).
  • Another method of determining the extent of activation is determining the presence of surface receptors and surface immunoglobulins, such as those listed above.
  • U.S. Patent No. 4,402,934. These tests for lymphocyte activation are less than perfect; the positive predictive value of these tests may be as low as 60% to 70%.
  • the tetrazolium tests are subject to a myriad problems.
  • the MTT assay often generates false positive and false negative results. Rollino et al. (1995) J. Immunol. Methods 185:141-3; Nishida et al. (1992) Hum. Cell 5:87-98; Campos et al. (1974) Arch. Intern. Med. 133: 432- 6; and Ashburn et al. (1973) Blood 41 :9215.
  • the tetrazolium assay may underestimate the cytotoxicity of toxic agents and does not reliably measure blood mononuclear cell responses, te Boekhorst et al. (1993) Leukemia 7:1637-44; and Chen et al. (1990) Int. Arch.
  • the present invention encompasses methods of determining whether a test cell is cancerous and also determining if a lymphocyte is activated based on measurements of the activity of an esterase or other enzyme and comparison with the activity in cancerous or activated cells respectively.
  • one embodiment of the present invention is a method of determining if a cell in a biological sample is cancerous by providing a biological sample comprising at least one mammalian test cell; measuring the activity or level of a protein in the test cell, where the activity or level of the protein in a cancerous cell is altered from that in a non- cancerous cell; and comparing the activity or level of protein in the test cell to the level or activity of the protein in a non-cancerous cell, where the activity or level of the protein in the test cell altered from that in a non-cancerous cell indicates a probability that the test cell is cancerous.
  • Another embodiment of the present invention is a method of determining whether a cell in a biological sample is cancerous by providing a biological sample comprising at least one mammalian test cell; measuring the esterase activity of the cell; comparing the esterase activity of the cell to the esterase activity of a non-cancerous cell, where the esterase activity of the test cell elevated over the esterase activity of the non-cancerous cell indicates a probability that the test cell is cancerous.
  • the determination of the level of esterase activity is performed by adding to said sample a first reagent comprising a composition which, when cleaved by said esterase, produces a first product capable of producing a detectable signal; and detecting and measuring the level of said signal, where said level is indicative of the level of esterase activity in the cell.
  • the method further comprises a measurement of the ploidy of the test cell in a method by determining the DNA ploidy of the cell; and comparing the ploidy of the cell to the ploidy of a non-cancerous cell, where the ploidy of the test cell greater than the ploidy of a non-cancerous cell indicates a probability that the test cell is cancerous.
  • the point at which ploidy is determined in the test is irrelevant.
  • the determination of ploidy is performed by adding to the sample a second reagent capable of interacting with the chromosomal DNA and producing a detectable signal; and detecting and measuring the level of fluorescence, where the signal level is correlated to the ploidy of the cell.
  • the test cell can be an animal cell, preferably a human cell.
  • the human cell includes, but is not limited to, those derived from cervical, brain, lung, liver, stomach, prostate, breast, epithelial, blood, bone, bladder, or colon sources.
  • the biological sample can also be obtained from a cervical swab smear, or biopsy, blood or tissue sample.
  • the first reagent preferably comprises a composition which, when cleaved by said esterase, fluoresces. Suitable fluorescent compositions include, but are not limited to, fluorescein or a derivative of fluorescein.
  • the derivative of fluorescein includes, but is not limited to, fluorescein diacetate, carboxyfluorescein diacetate, halogenated fluorescein diacetate, carboxylated halogenated fluorescein diacetate, sulfofluorescein diacetate, azidofluorescein diacetate, fluoroscein monoacetate, carboxyfluorescein monoacetate, halogenated fluorescein monoacetate, carboxylated halogenated fluorescein monoacetate, sulfofluorescein monoacetate, azidofluorescein monoacetate, fluorescein conjugated to a sugar, fluorescein phosphate, fluorescein isothiocyanate, fluorescein isothiocyanate diacetate, carboxylated fluorescein, halogenated fluorescein and carboxylated, halogenated fluorescein, sulfofluorescein, and azidofluorescein.
  • the carboxylated halogenated fluorescein diacetate includes, but is not limited to, dichlorofluorescein diacetate and 6-carboxy-2',7'-dichlorofluorescein diacetate, and diacetyl-2,7-dichlorofluorescein.
  • the derivative of fluorescein includes, but is not limited to, fluorescein-di-O-D- galactopyranoside, and fluorescein digalactoside.
  • the second reagent is a DNA intercalating agent.
  • the DNA intercalating agent is ethidium bromide or propidium iodine.
  • Another embodiment of the invention is a method of determining if a cell in a biological sample is cancerous by providing a biological sample comprising at least one mammalian test cell; measuring the esterase activity in the cell by adding to the sample a compound which, when cleaved by the esterase, fluoresces; and detecting and measuring the fluorescence; comparing the esterase activity of the cell to the esterase activity of a non- cancerous cell, where esterase activity of the test cell elevated over the esterase activity of the non-cancerous cells indicates a probability that the test cell is cancerous.
  • the measurement of the ploidy of the test cell by measuring the ploidy of the cell by adding to said sample a second reagent capable of interacting with the chromosomal DNA and fluorescing; detecting and measuring the level of fluorescence, where the level of fluorescence is correlated to the ploidy of the cell; and comparing the ploidy of the cell to the ploidy of a non-cancerous cell, where a ploidy of the test cell greater than the ploidy of a non-cancerous cell indicates a probability that the test cell is cancerous. Detection of ploidy and esterase activity can be performed in any order.
  • Another embodiment of the invention is a method of measuring activation of a lymphocyte by providing a test lymphocyte susceptible to activation by a stimulant; contacting the test cell with the stimulant under conditions suitable for lymphocyte activation; measuring the esterase activity of the test cell at least three days after performing step (b); and comparing the esterase activity of the test cell to the esterase activity of a cell which has not been activated, where esterase activity of the test cell altered from the esterase activity of a cell which has not been activated indicates a probability that the test cell has been activated.
  • Another embodiment of the invention is a method of measuring activation of a lymphocyte, wherein the determination of the level of esterase activity by adding to said sample a first reagent comprising a composition which, when cleaved by said esterase, produces a first product capable of producing a detectable signal; and detecting and measuring the level of said signal, where said level is indicative of the level of esterase activity in the cell.
  • the cleavage of a fluorescein derivative is correlated with activation of the lymphocyte.
  • the fluorescein derivative is fluorescein diacetate.
  • Another embodiment of the invention is a method of measuring activation of a lymphocyte, wherein the determination of activation of the test cell is further confirmed by measuring the reduction by the cell of a test compound, wherein said reduction is positively correlated to activation; and measuring the expression of an antigen, wherein expression of the antigen is positively correlated to activation.
  • the test compound is a tetrazolium.
  • the tetrazolium includes, but is not limited to, 2,3-bis (2-methoxy-4-nitro-5-sulfo-phenyl)-2H- tetrazolium-5-carboxanilide (XTT) or 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H- tetrazolium bromide (MTT).
  • XTT 2,3-bis (2-methoxy-4-nitro-5-sulfo-phenyl)-2H- tetrazolium-5-carboxanilide
  • MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H- tetrazolium bromide
  • the antigen is selected from CD69, CD25, CD69, CD71, and 4F2.
  • the antigen is CD69.
  • expression of the antigen is measured by an immunoassay or quantification of mRNA production.
  • activation is mediated by at least another stimulant selected from lectins, mitogens, antigens, antibodies, or other cells.
  • Figure 1 depicts the pattern of fluorescence of a fluorescein derivative in normal cervical cells (A), cervical squamous carcinoma cells (B), and normal endometrial cells (C).
  • Figure 2 is a bar graph depicting a fluorescein diacetate (FDA) colorimetric assay of unstimulated (gray bars) and allo-stimulated (solid bars) MLR.
  • FDA fluorescein diacetate
  • the present invention encompasses methods of determining whether a test cell is cancerous based on measurements of ploidy and/or the activity of an enzyme, where the level of enzyme activity is altered in a cancerous cell compared to a non-cancerous cell. The present invention also encompasses methods of determining if a lymphocyte is activated or not.
  • enzyme is meant any protein with catalytic activity, including binding and/or cleaving or modifying a substrate.
  • the enzyme has an altered activity level in cancerous cells.
  • Enzymes known to have altered levels of activity in cancerous cells include, but are not limited to: l lql3 locus. Brison (1993) Biochim. Biophys. Acta 1155:25-41. 2-5A synthetase. Merritt et al. (1985) Prog. Clin. Biol. Res. 202:423-30.
  • Calpactin I annexin II light chain. Wildrick et al. (1992) Anticancer Res. 12:1721- 4.
  • Carcinoembryonic antigen (CEA). Hamori et al. (1997) Acta Chir. Hung. 36L125- 7; Zaleska et al. (1997) Rocz. Akad. Med. Bialymst. 42 (suppl. 1): 179-89; and Alters et al. (1991) Adv. Exp. Med. Biol. 417:519-24.
  • Heparin-binding growth factor type 2/basic fibroblast growth factor (HBGF- 1/bFGF). Sternfeld et al. (1988) J. Cell. Physiol. 136:297-304.
  • HOX2 homeobox gene Simeone et al. (1990) Nature 346:763-6; and Faiella et al. (1994) Proc. Natl. Acad. Sci. USA 91 :5335-9. Inosine 5'-monophosphate dehydrogenase (IMP DH). Weber et al. (1991) Cancer
  • IGF2 Insulin-like growth factor II
  • Melanoma antigen-encoding gene-1 (MAGE-1).
  • MAP Mitogen-activated protein
  • NDP Nucleoside diphosphate
  • P815AB tumor antigen encoded by P1A Uyttenhove et al. (1997) Int. J. Cancer 70:349-56. P53. Lacombe et al. (1996) J. Clin. Oncol. 14:2646-52; and Freedman et al. (1996)
  • PKA Protein kinase A
  • PLC Protein kinase C
  • Pyrimidine nucleoside phosphorylase (PyNPase). Kirita et al. (1995) Gan To Kagaku Ryoho 22:509-14. Ras, K-ras. H-ras, N-ras oncogenes. Brison (1993) Biochim. Biophys. Acta
  • TCR T-cell receptor
  • Thymidylate synthase Speth et al. (1988) Clin. Pharm. Ther. 44:369-75.
  • Tissue inhibitor of metalloproteinases Tissue inhibitor of metalloproteinases (TIMP). Vascular endothelial growth factor. White et al. (1995) Growth Factors 12:289-
  • the enzyme whose change in activity is detected by the method of the present invention is an esterase.
  • the esterase is capable of cleaving a reagent, and more preferably, the esterase cleaves a fluorescein derivative to produce a fluorescent product.
  • Esterases include, but are not limited to, nonspecific esterases, alpha- esterase, ⁇ -Kesterase, naphthol chloracetate esterase (NCAE); guanidinobenzoate esterase; alpha naphthyl acetate esterase (ANAE); and other esterases.
  • a positive naphthol AS-D chloroacetate esterase stain in granulocytic sarcoma is a differential diagnosis between malignant lymphoma and granulocytic sarcoma. Spahr et al. (1982) Acta Cytol. 26:55-60.
  • Non-specific esterases commonly demonstrate an increase in activity in cancerous tissues.
  • An increase in the production of nonspecific tissue Kesterase (NTE) accompanies formation of endometrial malignancies.
  • NTE content in uterine tissues and mucus of patients with cancer of endometrium correlates with a degree of differentiation, spreading and depth of tumor cell invasion into the myometrium. Volodin (1986) Eksp. Onkol. 8:49-
  • Non-specific esterase activity was also demonstrated in tumor cells from a tumor located in the anterior mediastinum. Oosterhuis et al. (1991) Cancer Genet. Cytogenet. 54:183-95. Elevated levels of non-specific esterase were also found in leukocytes in patients with severe leukopenia. Zubrikhina et al. (1990) Vopr. Onkol. 36:81-85. The amounts of fluoride-sensitive and -resistant nonspecific esterase activity increased with the progression of malignancy of erythroleukemic cells. Woytowicz et al. (1983) Blood 62:425-32. Significant nonspecific esterase positivity was also observed in bone tumor sections. Wood (1978) J. Pathol. 125:53-8.
  • a positive naphthol AS-D chloroacetate esterase stain in granulocytic sarcoma may be used as a differential diagnosis between malignant lymphoma and granulocytic sarcoma. Spahr et al. (1982) Acta Cytol. 26:55-60. In solid Ehrlich ascite tumor cells, the activity of naphthol- AS-acetate esterase was significantly higher than in other cells. Bauer et al. (1977) Arch. Geschwulstforsch 47:236-40. Urinary alpha-esterase levels were elevated in bilharzial bladder cancer patients compared to normal controls, el- Sewedy et al. (1978) Trans. R. Soc.
  • esterase D an enzyme mapping to 13ql4.11
  • a null allele of esterase D is a marker for genetic events in retinoblastoma formation.
  • N-acetyl arginine esterase activity may also be lower in malignant mucosa cells. Paskhina et al. (1984) Vopr. Med. Khim. 30:87-96.
  • determination of esterase levels of a cancer cell are made in comparison to esterase levels in a normal cell of the same or a similar type of tissue. Altered levels or activities of an esterase or any other protein may be determined by any of a number of techniques. For example, standard methods of molecular biology such as Western blots can be used to detect increased abundance of a protein product; Northern blots can be performed to detect increases in levels of the corresponding mRNA.
  • Antibodies to specific proteins can also be conjugated to fluorescent markers or enzymes that modify a substrate to produce a detectable signal, or conjugated to the signal-producing moiety itself.
  • fluorescent markers or enzymes that modify a substrate to produce a detectable signal
  • Such techniques are commonly known in the art and described, for example, in Molecular Cloning: A Laboratory Manual, 2nd ed., Vol. 1-3, eds. Sambrook et al. Cold Spring Harbor Laboratory Press (1989); and Current Protocols in Molecular Biology, eds. Ausubel et al., Greene Publishing and Wiley-Interscience: New York (1987) and periodic updates.
  • enzymes such as esterases
  • enzyme cleavage of a natural or artificial substrate can produce a detectable signal.
  • esterases cleave substrates such as fluorescein-derived compounds and thereby produce a fluorescent product. The level of fluorescence is correlated to the abundance of the esterase.
  • fluorescein-derived compound By “fluorescein-derived compound”, “fluorescein derivative”, and the like, is meant any compound which can be cleaved by an esterase to produce a fluorescent compound.
  • a fluorescent compound is meant a compound which fluoresces when exposed to an appropriate level and wavelength of light, as is well-known in the art. For example, when excited by blue light, fluorescein emits an intense yellow-green fluorescence. Preferably, this compound comprises fluorescein or a derivative of fluorescein.
  • the derivatives of fluorescein include, but are not limited to, fluorescein diacetate, carboxyfluorescein diacetate, halogenated fluorescein diacetate, carboxylated halogenated fluorescein diacetate, sulfofluorescein diacetate, azidofluorescein diacetate, fluoroscein monoacetate, carboxyfluorescein monoacetate, halogenated fluorescein monoacetate, carboxylated halogenated fluorescein monoacetate, sulfofluorescein monoacetate, azidofluorescein monoacetate, a compound comprising fluorescein conjugated to a sugar, fluorescein phosphate, fluorescein isothiocyanate (FITC), fluorescein isothiocyanate diacetate, carboxylated fluorescein, halogenated fluorescein and carboxylated, halogenated fluorescein, sulfofluorescein, and azid
  • Carboxyfluorescein include, but are not limited to, fluorescein diester, 5-carboxyfluorescein diacetate, and 6-carboxyfluorescein diacetate.
  • Carboxylated halogenated fluorescein diacetates include, but are not limited to, 5-carboxy-2',7'-dichlorofluorescein diacetate and 6-carboxy-2',7'-dichloro fluorescein diacetate, and diacetyl-2,7-dichlorofluorescein.
  • a fluorescein derivative include, but are not limited to, fluorescein-di- ⁇ -D-galactopyranoside, and fluorescein digalactoside.
  • the fluorescein derivative is fluorescein diacetate or FITC.
  • a test cell has an esterase level typical of a cancer cell can be made by first staining the test cell with a fluorescein derivative.
  • the fluorescein derivative enters the cell, where it is cleaved by an esterase to produce a fluorescent product.
  • the cell is then placed under conditions wherein the fluorescent product fluoresces (e.g., placed in a cell sorter and exposed to a light of a wavelength suitable for exciting the fluorescent product to produce a light signal).
  • Cell sorters and automated detectors of fluorescence are known in the art.
  • cancerous cells can also demonstrate an altered ploidy.
  • ploidy is meant an indication of the number of sets of chromosomes within a cell. Monoploid indicates the basic or haploid number of chromosomes; diploid is twice this number. Euploidy also indicates a correct number of chromosomes (e.g., a diploid number).
  • a cancer cell is "aneuploid” if it does not have the normal diploid number due to chromosome loss or an excess in chromosomes.
  • Hapoploidy indicates loss of portions of or complete chromosomes.
  • Hype ⁇ loidy or “hyperdiploidy” indicates that a cell contains more than the diploid number.
  • chromosome number averaging at least 1.1 or 1.2 times the diploid number indicates hype ⁇ loidy or hyperdiploidy. These two latter terms partially overlap with the terms “tetraploidy” (twice the diploid number) and “hypertetraploidy” (more than twice the diploid number).
  • Aneuploidy has been used as both an indicator of the malignancy of tumors, and an indicator of possible outcome. Patients in which tumors demonstrate aneuploidy may have a significantly shorter survival rate than those with euploid tumors.
  • Hype ⁇ loidy is correlated with high grade dysplasia of cervical-vaginal cytology smears. Kurtycz et al. (1996) Diagn. Cytopathol. 15:46-51.
  • aneuploidy is correlated with a number of different types of cancer, including, but not limited to, lung carcinoma, lymphoblastic leukemia, and pancreatic, colonic, colorectal and urothelial cancer, and the correlation between malignancy and aneuploidy has been studied particularly thoroughly with breast cancer tumors.
  • FISH fluorescence in situ hybridization
  • intercalating agent any agent capable of binding to DNA to produce a fluorescent product.
  • a fluorescent compound is meant a compound which fluoresces when exposed to an appropriate level and wavelength of light, as is well-known in the art. For example, when excited by ultraviolet light, ethidium bromide produces a visible light signal.
  • the intercalating agent includes, but is not limited to, ethidium bromide. propidium iodide, or another large planar compound capable of inserting itself between the bases in DNA. Fluorescence is correlated with the amount of DNA in the cell and thus indicative of relative ploidy.
  • Ethidium bromide and other intercalating agents have been used to differentiate between living and dead cells, with the agents permeating the leaky cell membranes of dead cells, but not the intact cell membranes of living cells.
  • cell membranes In order to stain living cells for staining with ethidium bromide, cell membranes must be permeabilized. Preferably, this is done by exposing the cells for a short time with a low (non-toxic) level of a detergent. Suitable detergents include, but are not limited to, Triton X-100TM (polyoxyethylene-p-t- octylphenol) and Nonidet P-40TM .
  • cells in a solution of intercalating agent are micro-injected or exposed to a very short electrical shock (e.g., 2000 volts per centimeter for 200 microseconds), which causes transient pores to form in the plasma membrane without damaging intracellular membranes. The pores remain open for minutes or hours, depending on the cell type and degree of the electric shock, allowing entry of the intercalating agent.
  • a very short electrical shock e.g. 2000 volts per centimeter for 200 microseconds
  • membrane-bounded vesicles containing the intercalating agent can be induced to fuse with the plasma membrane of the cells. This allows entry of the intercalating agents into the cells.
  • Vesicles can be formed by any technique known in the art, including, for example, mixing a concentrated solution of intercalating agent with a suspension of phospholipids and agitating the suspension ultrasonically to create liposomes.
  • red blood cells can be converted into loaded membrane-bound vesicles by bursting them to remove their natural contents and then allowing their plasma membranes to reseal while immersed in a solution of intercalating agent.
  • Either the liposomes or red cell ghosts can be induced to fuse with the target cells by the presence of certain viral fusion-inducing proteins (produced by the viruses to help them get into the cells). Gomperts et al. (1985) Trends Biochem. Sci.
  • a determination of ploidy can be made by first staining the test cell with an intercalating agent. This agent enters the cell, where it interacts with the chromosomal DNA to produce a fluorescent product. The cell is then placed under conditions wherein the fluorescent product fluoresces (e.g., placed in a cell sorter and exposed to ultraviolet light). Within the cell sorter, the signal is detected and quantified. Cells known to be cancerous or non-cancerous are treated in the same way to determine typical ploidies of these cells. Finally, a comparison is made between the fluorescence of the fluorescent product in the test cell with that of the same product in the cancer and non-cancerous cells.
  • cancerous cells will have a higher fluorescence due to higher ploidy than non- cancerous cells.
  • An indication that the test cell has an altered esterase activity and an altered ploidy compared to a non-cancerous cell indicates a probability that the test cell is a cancer cell.
  • the present invention also encompasses methods of using fluorescent reagents to detect activated lymphocytes.
  • Lymphocyte is meant any immunological cell with a large nucleus and relatively thin layer of cytoplasm, including, but not limited to, T cells, B cells, monocytes, neutrophils, eosinophils. and basophils. Lymphocytes can be activated by external stimulation, e.g. culture in the presence of any stimulant, including but not limited to, a cytokine, lectin, antigen (including, but not limited to, allo-antigens and superantigens), antibody, or another cell (e.g. in a MLC).
  • stimulant including but not limited to, a cytokine, lectin, antigen (including, but not limited to, allo-antigens and superantigens), antibody, or another cell (e.g. in a MLC).
  • Mononuclear cells for example, can be activated by culturing them ex vivo in the presence of tumor cell extract and a non-specific activator like phytohemagglutinin or IL-1.
  • a non-specific activator like phytohemagglutinin or IL-1.
  • MLR Multiple lymphocyte reaction
  • MLR mixed lymphocyte culture
  • MLC multiple lymphocytes
  • the cells are cultured together for a time and under suitable conditions to result in the stimulation of the lymphocytes.
  • a frequent objective of MLC is to provide allogeneic stimulation to initiate proliferation of the lymphocytes; but unless indicated, proliferation during the culture is not required.
  • these terms can alternatively refer to a mixture of cells derived from such a culture.
  • cytoimplant When cells from MLC are administered as a bolus to a human, especially in a tumor bed, it is referred to as a "cytoimplant".
  • the therapeutic effect or immunologic response can be boosted by implanting in or around the bed of a solid tumor in the patient a second cell population comprising alloactivated human lymphocytes allogeneic to the patient.
  • a second cell population comprising alloactivated human lymphocytes allogeneic to the patient.
  • Multiple cytoimplants or combinations of implants and cellular vaccines could be given to the same patient, but some attention should be paid to the possibility that the allogeneic lymphocytes in the vaccine may generate an anti-allotype response.
  • the use of a mixture of allogeneic cells from a plurality of donors, and the use of different allogeneic cell populations in each dose, are both strategies that can help minimize the occurrence of an anti-allotype response.
  • cells are tested to determine if they are normal or cancerous and lymphocytes are tested to determine if they are unactivated or activated. Such determinations are based on the findings, described above, that cancerous cells have altered protein or enzyme levels or activities.
  • the protein or enzyme level or activity of the test cell is determined and compared to that of a non-cancerous cell.
  • a cancerous cell can also be used as a control.
  • the ploidy of the test cell can be determined and compared to that of a non-cancerous cell control. Altered enzyme levels or activity and altered ploidy indicate that the cell is cancerous.
  • test cells are obtained through any technique known in the art, including, but not limited to, extraction of bodily fluids or mechanical abrasion such as curettage or washing.
  • Pap smear material is collected by standard techniques for analysis.
  • cells can be suspended in saline by agitation with the extraction instrument (e.g, brush or spatula) in a test tube containing the fluid.
  • Test cells are then exposed to a first reagent which tests the level or activity of a given protein or enzyme known to have an altered level or activity in a cancer cell.
  • the protein is an enzyme, and more preferably, an esterase.
  • the first reagent can be, for example, an antibody, an antibody conjugated to a enzyme that cleaves a substrate to produce a detectable signal, or an antibody conjugated to a substrate cleaved by an enzyme to produce a detectable signal.
  • the reagent can be a radio- labeled polynucleotide probe used to detect levels of the mRNA translated to produce the protein or enzyme.
  • the first reagent is, preferably, a substrate which is cleaved by the enzyme to produce a detectable signal. More preferably, in the case of esterases, the reagent is a substrate cleaved to produce a fluorescent signal.
  • the reagent is a fluorescein-derivative.
  • the use of antibodies, probes and fluorescent reagents is known in the art and exemplified in, for example, Molecular Cloning: A Laboratory Manual, 2nd ed., Vol. 1-3, eds. Sambrook et al. Cold Spring Harbor Laboratory Press (1989); and Current Protocols in Molecular Biology, eds. Ausubel et al., Greene Publishing and Wiley-Interscience: New York (1987) and periodic updates and references cited therein.
  • the level of the signal generated is then detected.
  • the substrate is then added to the cell and the signal detected.
  • the enzyme is then added to the cell and the signal detected.
  • the cells may be placed into a flow cytometer and the fluorescence detected, as is known in the art.
  • Non-cancerous and cancerous cells may be treated in the same way and used as a control; a level of signal dissimilar to that of a non- cancerous cell and similar to that of a cancerous cell indicates that the test cell is cancerous.
  • the test cell may be tested for ploidy. Several techniques are listed above for determining ploidy.
  • the cells are treated with a second reagent which binds to the chromosomes of the test cell and produces a fluorescent product. More preferably, the cells are treated with a detergent and an intercalating agent. More preferably, the intercalating agent is ethidium bromide or propidium iodide.
  • the level of fluorescence of the cells can be determined by any method known in the art, including, preferably, passing the cells through a flow cytometer, which will measure the fluorescence of the cells and thereby determine the cell's ploidy.
  • a determination that the cell has an altered ploidy is an indication that the test cell is cancerous.
  • An indication that the test cell is aneuploidy and has an altered esterase level provides greater assurance that the cell is cancerous.
  • fluorescent reagents such as fluorescein diacetate are used to determine whether cells are cancerous and whether lymphocytes are activated.
  • another fluorescent agent such as an intercalating agent (e.g., ethidium bromide or propidium bromide) can also be used to determine ploidy, or a test can be performed to determine expression of cancer-specific markers.
  • Test cells can be obtained from a patient through any techniques known in the art, such as extraction of bodily fluids or mechanical abrasion such as curettage or washing.
  • Pap smear material can be collected by standard techniques for analysis. Lymphocytes can be tested after exposure to antigens for activation.
  • test cells are suspended in phosphate-buffered saline (PBS). Then the cell suspension is stained for 30 minutes at room temperature by the addition of a final concentration of about 0.01 to about 0.1 ⁇ g/ml fluorescein diacetate (stock in DMSO). After a brief (10 to 20 min) fixation in 0.5% paraformaldehyde, cells are optionally further stained by the addition of 0.1 to 1 ⁇ g/ml ethidium bromide (or propidium iodide) and 0.05% Triton-X100TM detergent.
  • PBS phosphate-buffered saline
  • test cells are analyzed for their fluorescent properties using a fluorescence activated cell sorter (FACS) or fluorescence microscope.
  • FACS fluorescence activated cell sorter
  • the level of fluorescence of the fluorescein compound and the intercalating agent, which are correlated to the relative levels of esterase activity and ploidy, are measured and recorded, preferably. automatically. These results are compared to control results obtained from cells known to be cancerous and/or normal or non-cancerous, or, in the case of lymphocytes, compared to cells known to activated or unactivated.
  • Cancerous and non-cancerous tissues were used to verify the validity of the use of fluorescent compounds to determine if cells were cancerous.
  • Material from a hysterectomy specimen was obtained, stained and analyzed by flow cytometry as described above.
  • the specimens came from a 64-year-old female with cervical squamous cell carcinoma.
  • Samples were also taken from a normal cervix (A), a cervical carcinoma (B), and normal endometrium (C), by swabbing the specimen gently with a cotton swab.
  • a fluorescent reagent such as FDA (fluorescein diacetate) can be used to identify abnormal cells in a Pap smear material.
  • flow cytometry can be used to identify abnormal cells.
  • pathology material usually from hysterectomy specimens.
  • Various areas of each specimen were swabbed with cotton swabs, thereby collecting an assortment of cell populations, such as cells from ectocervix (outer cervical surface), endocervix (inner portion or cervix), or endometrium (mucus membrane lining uterus).
  • EXAMPLE 4 Analysis of cancerous cells using intercalating agents Should fluorescent reagents indicate that cells in a particular sample are cancerous, this finding can be optionally confirmed by used of an intercalating agent. Such an agent can be used to determine the ploidy of a test cell; cancerous cells are typically aneuploid.
  • Test cells described above were stained by the addition of 0.1 to 1 ⁇ g/ml ethidium bromide (or propidium iodide) and 0.05% Triton-XlOOTM non-ionic detergent. Cells were then passaged through a flow cytometer and a comparison of the results with those of cells of a normal sample indicated that the test cells were aneuploidy. This provided an independent confirmation of the results of Example 2, and a further indication that the test cells were cancerous.
  • a fluorescent reagent such as FDA is a useful measure of lymphocyte activation, both early in the course of lymphocyte activation and late.
  • Mononuclear cells or whole blood containing lymphoid cells are activated, for example, with lectins, antibodies, superantigens, or alloantigens, by any mechanism known in the art.
  • Activated cells are stained with a fluorescent reagent such as FDA and analyzed by flow cytometry. Stained cells can also be treated with labeled antibodies, such as Phycoerythrin-labeled antibodies to specific lymphoid subsets, to analyze the state of activity of the various subsets.
  • the data in the Table 2 below compares various measurements of activated lymphocytes performed 3 days after activation. These values are compared with the results obtained after 7 days.
  • Mononuclear cells from 10 unrelated donors were activated by an alloantigen by mixing donor cells with stimulator cells at a ratio of 10:1 on day 0 and incubating the cells in RPMI medium supplemented with 2% FCS (fetal calf serum) at 37 C. T cells from these preparations were analyzed as described below at the times indicated. Blasts were quantified by making a cytospin smear of the preparation and counting the number of blasts and total number of cells after Wright-staining. Cells were also analyzed by FDA staining after 7 days. Both control unstimulated cells and activated cells were analyzed and the results below represent the percentage above control values for each mixed lymphocyte reaction. This is done because of the high variability of background activity in unstimulated donor cells. Any value at least 10% over control is considered significant. %
  • Predictive value represents the ability of a test to predict an activated MLR (mixed lymphocyte reaction) as judged by comparing the values with blastogenesis after 1 week. Since all cultures had a large number of blasts, the % predictive value is calculated by dividing the percent of cases, showing at least 10% above control, by 100%.
  • FDA staining is a better predictor of lymphocyte activation than Formazan reduction (XTT) tests or measuring CD69, a marker for lymphocyte activation.
  • Use of XTT had a predictive value of only 60%; determining CD69 antigen expression had a predictive value of only 70%.
  • Use of FDA had a predictive value of 80% after 3 days and 100% after 7 days. FDA is also useful for measuring lymphocyte activity after stimulation with lectins.
  • a colorimetric plate assay can also be performed using FDA to measure lymphocyte activation. Day 3 alloactivated cultures similar to those described above were stained with FDA for 1 or 1.5 hours in a 96- well plate. Using a colorimetric ELISA-style plate reader, an OD 494 nm could be obtained.
  • Fig. 2 The data are presented in Fig. 2 and indicate that, for example, after 1 hr of incubation at 37°C, unstimulated MLR demonstrated an OD494 of around 250, while allostimulated (activated) MLR had an OD of around 375.
  • the colorimetric plate assay can be used to monitor the activation of lymphocytes.
  • lymphocyte activation is performed on surrogate cultures, as well as on the final product, such as the cytoimplant to be used in a human patient. Bioactivity of the cultured lymphocytes is measured using a Tetrazolium (XTT) reduction assay. Levels of culture reduction capacity is compared to unstimulated cultured donor cells on day 1 through 3 of the surrogate cultures and on day 3 for the final product.
  • XTT Tetrazolium
  • Inte ⁇ retation and validation of these assays requires that each activity be compared to the appropriate unstimulated control cultures.
  • the activity of the allo-activated cells is compared to unactivated, cultured cells.
  • Surrogate cultures are used so that cultures are maintained at a concentration of 0.5 X 10 6 /mL in order to minimize the background autologous activation.
  • Final product activity is compared to the activity of the culture on day 0.
  • the cells used in this culture must be from the same pheresis products used for making the cytoimplant.
  • AIM-V medium with 2% heat inactivated donor plasma or 2% fetal calf serum is used for culture medium.
  • Reagents include: XTT [2,3-bis (2-methoxy-4-nitro-5-sulfo-phenyl)-2H- tetrazolium-5-carboxanalide salt], which is dissolved in sterile DPBS (Dulbecco's Phosphate Buffered Saline) at a concentration of 1 mg/mL and stored frozen protected from light; and PMS (Phenyl methane sulfonyl fluoride - a toluene sulfonyl fluoride), which is dissolved in sterile DPBS at a concentration of 1.53 mg/mL and also stored frozen protected from light.
  • XTT 2,3-bis (2-methoxy-4-nitro-5-sulfo-
  • Additional materials include: a 96-well flat-bottomed micro-culture plate; an ELISA plate reader capable of reading at 470 nm with reference 650 nm; and polypropylene capped sterile culture tubes.
  • XTT solution at 5 ⁇ L of PMS per mL of XTT solution, immediately before adding to the wells. (Pre-mixed reagents may cause incorrect results.)
  • XTT/PMS 50 ⁇ L is added per well and incubated at 37°C for 4 hr. After this incubation, the plate is read at 470 nm reference to 650 nm in an ELISA plate reader. Average values for each culture are recorded.
  • the percent increase of cytoimplant values over donor alone values is calculated.
  • the value for an MLC suitable for use in a human patient must be at least 10% above the control value. Note that the acceptable MLC Value must be > 10% above the Control Value.
  • Acceptable MLC value Actual Control Value + 10% of Actual Control
  • Samples of frozen medium control and reconstituted frozen positive control samples should be assayed. First, medium control is thawed and 100 ⁇ L samples assayed in duplicate as described above. Next, positive control samples are thawed and diluted 100- fold with thawed control medium. 100 ⁇ L samples are assayed in duplicate as described above.
  • Medium control is prepared on an as-needed basis in lots of 200 individual tubes by aliquoting 500 ⁇ L of sterile RPMI medium supplemented with 2% FCS. Aliquots are frozen and held at -20°C until needed.
  • Positive control samples are prepared on an as-needed basis in lots of 200 individual tubes. Human mononuclear cells not needed for cytoimplant production can be used to produce these control samples. Mononuclear cells are activated for 24 hours by incubating the cells at 37°C in RPMI with 10% FCS supplemented with 10 ⁇ g/mL
  • Phytohemagglutinin (PHA, Sigma) at 1 X 10 6 cells/mL. After culture, a cytospin slide stained with Diff-Quick (Baxter) can be visualized to identify the presence of lymphoblasts. If none are present, the cells are cultured for another 24 hours, or else other mononuclear cells or a different aliquot of PIIA is used. If blasts are present, the cells are centrifuged at 1000 X g for 10 minutes, the supernatant is replaced with 4°C Freezing Medium at the rate of 2 mL for every 100 mL of original culture. Samples (50 ⁇ L) are aliquoted in individual tubes and freeze.
  • MLC activation is defined as increased activity above that obtained for unstimulated control cultures at a statistically significant level, this test becomes a good predictor of activity.
  • Statistical significance is defined as MLC values failing the null hypothesis at the 0.025 significan level using a Student's t-test (or generally at least 10% above control levels in duplicate assays, without overlapping error bars).
  • Positive predicative value 60% (false negatives 40%, p ⁇ 0.025)
  • Negative predicative value 100% (false positives 0%, p ⁇ 0.025)
  • Lymphocyte activation is demonstrated by measuring increased cell surface expression of CD69 using specific fluorescently-labeled antibodies or by measuring increased intercellular esterase activity using fluorescein diacetate. Both methods can be used in conjunction with CD3-labeling using specific monoclonal antibodies labeled with a second fluorochrome. Both of these methods have been validated by comparing increased percentages of CD69-ove ⁇ roducing or esterase-ove ⁇ roducing cells with other measures of lymphocyte activation. Unstimulated lymphocytes do not express surface antigen CD69 and have only low levels of non-specific esterases.
  • CD69 Once activated by allo-antigens or nonspecific mitogens, the expression of CD69 appears within 4 to 8 hours (peak at 24) and esterase activity increases shortly after stimulation and continues for several days. Not all allo-stimulated lymphocyte reactions proceed with the same kinetics. To ensure that these measures accurately reflect "activity" in all active cytoimplants, activity is measured on day 1-3 of the cultures. Small samples of donor cells alone and of the cytoimplant are incubated separately and are used to test activity.
  • Reagents include: Monoclonal Antibodies CD3-PE (Coulter) and CD69-FITC (Becton-Dickinson), which are kept refrigerated when not in use and protected from light.
  • Fluorescein Diacetate (Sigma) is prepared as a stock solution in 10 mg/mL in DMSO, protected from light, and stored in frozen tested aliquots. A working solution is made weekly by diluting the stock 1:100 in DMSO, and keeping it refrigerated and protected from light.
  • Flow cytometer such as an Epics XL Coulter Flow Cytometer Quality Controls include: Internal control unstimulated and activated mononuclear cell samples are produced on an as-needed basis. Large lot-tested batches are frozen under liquid nitrogen in 250 Tl aliquots in 10% DMSO freezing medium.
  • Mononuclear cells from normal donors are used to produce activated control specimens.
  • Mononuclear cells from a normal donor for a given cytoimplant are often in excess and some of these cells can be used to make control samples. These cells are placed in 2% FCS-RPMI at 3.0xl0 6 cell/mL up to 100 mL. Cells are cultured for 2 days at 37°C in the presence or absence of 2 Tg/mL PHA lectin or admixed at a ratio of 10:1 with a second donor population. These calls are collected by centrifugation at 350 x g for 5 minutes. The medium is removed and replaced by 1/10th the volume of DMSO Freezing medium. The cells are frozen.
  • control unstimulated and stimulated cells can be thawed quickly and resuspended at the original volume by adding nine volumes of PBS.
  • Control cells are analyzed to the protocol below along with cytoimplant samples. Cells are then gently vortexed and incubated 30 minutes at room temperature. 2 mL of PBS (4°C) is added and the sample centrifuged at 1200 RPM for 10 minutes. The supernatant is decanted. 0.5 mL of 0.5% paraformaldehyde-0.05% Triton-XlOO PBS is added and the solution mixed. Cells may be analyzed for fluorescence immediately or may be analyzed up to 2 weeks later if stored in a refrigerator. If RBCs are present, tubes are checked for lysis. When about 4000 cells are counted, the cytometer is stopped.
  • Each test is accompanied by an internal control. Both medium control and pH-stimulated control mononuclear cells are available . These are processed as described above in parallel and analyzed. While the actual values may vary from test to test, the degree of stimulation over unstimulated controls should be reproducible.
  • lectin-activated mononuclear cells are serial diluted with equivalent numbers of unactivated cells. After analysis of these samples as described above, the plot of % activated cells versus dilution factor should produce a linear relationship.
  • Positive predicative value 70% (false negatives 30%, p ⁇ 0.025)
  • Negative predicative value 100% (false positives 0%, p ⁇ 0.025)
  • Positive predicative value 80% (false negatives 20%, p ⁇ 0.025)
  • Negative predicative value 100% (false positives 0%, p ⁇ 0.025)
  • CD69 Use of a fluorescent reagent such as fluorescein diacetate.
  • the three assays can be used on the same cell sample. Each assay thus serves to confirm the results obtained with the other two assays.
  • activation is defined as activation at least 10% greater than the control unstimulated cells, tested on days 1, 2, or 3 of culture.
  • Negative predicative value 100% (false positives 0%, p ⁇ 0.025)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés qui permettent de déterminer, d'une part, si des cellules d'essai comprises dans un prélèvement sont cancéreuses ou non, et, d'autre part, si des lymphocytes sont activés ou non. Le procédé est mis en oeuvre pour mesurer la ploïdy d'ADN des cellules d'essai ainsi que l'activité cellulaire d'une enzyme, telle qu'une estérase, dont l'expression est altérée dans des cellules cancéreuses. L'activité de l'enzyme estérase peut être mesurée au moyen de composés fluorescents tels que le diacétate de fluorescéine.
PCT/US1999/015401 1998-07-08 1999-07-08 Utilisation de reactifs fluorescents pour identifier des lymphocytes cancereux ou actifs Ceased WO2000003033A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU52091/99A AU5209199A (en) 1998-07-08 1999-07-08 Use of fluorescent reagents in identification of cancerous cells and activated lymphocytes
US09/755,880 US6696241B2 (en) 1998-07-08 2001-01-04 Measuring esterase activity using fluorescent substrates as a way of evaluating cervical cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9221098P 1998-07-08 1998-07-08
US60/092,210 1998-07-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/755,880 Continuation US6696241B2 (en) 1998-07-08 2001-01-04 Measuring esterase activity using fluorescent substrates as a way of evaluating cervical cancer

Publications (2)

Publication Number Publication Date
WO2000003033A1 true WO2000003033A1 (fr) 2000-01-20
WO2000003033A9 WO2000003033A9 (fr) 2000-10-05

Family

ID=22232175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015401 Ceased WO2000003033A1 (fr) 1998-07-08 1999-07-08 Utilisation de reactifs fluorescents pour identifier des lymphocytes cancereux ou actifs

Country Status (3)

Country Link
US (1) US6696241B2 (fr)
AU (1) AU5209199A (fr)
WO (1) WO2000003033A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075718A1 (fr) * 2006-12-19 2008-06-26 Riken Molécule fluorescente

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625730B2 (en) * 2002-06-24 2009-12-01 Sysmex Corporation Method for classifying and counting leukocytes
US8208142B2 (en) * 2003-12-24 2012-06-26 King Salid University Lung cancer detection by optical analysis of body fluids
US7869033B2 (en) * 2003-12-24 2011-01-11 Vadivel Masilamani Cancer detection by optical analysis of body fluids
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
US20080014147A1 (en) * 2006-02-28 2008-01-17 The University Of Tokyo Tumor specific fluorescent dye
EP2038651B1 (fr) * 2006-06-29 2017-03-29 Koninklijke Philips N.V. Procédé de détection et/ou de diagnostic in vitro d'un cancer au moyen de la cytométrie d'image d'adn basée sur le rayonnement uv
DE102013220896A1 (de) 2013-10-15 2015-04-16 Bgd Boden- Und Grundwasserlabor Gmbh Verfahren und Kit zur Bestimmung der Esteraseaktivität in biologisch aktiven Umweltproben

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635402A (en) 1992-03-05 1997-06-03 Alfano; Robert R. Technique for determining whether a cell is malignant as opposed to non-malignant using extrinsic fluorescence spectroscopy
US5776720A (en) 1995-05-18 1998-07-07 Coulter Corporation Assay reagent
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5733719A (en) 1995-05-18 1998-03-31 Coulter Corporation Method of making an assay compound
US5871946A (en) 1995-05-18 1999-02-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5905031A (en) 1995-05-18 1999-05-18 Coulter International Corp. Identification of blast cells in a leukocyte cell preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORVER ET AL: "One-Tube Triple Staining Method for Flow Cytometric Analysis of DNA Ploidy and Phenotypic Heterogeneity of Human Solid Tumors Using Single Laser Excitation", CYTOMETRY, vol. 25, 1996, pages 358 - 366, XP002925061 *
LUND-PERO ET AL: "Reduced Nonspecific Steroidal Esterase Activity in Human Malignant Tumor Tissue from Liver, Colon and Breast when Compared to Peritumoral and Normal Tissue Levels", ANTICANCER RESEARCH, vol. 14, 1994, pages 2747 - 2753, XP002925060 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075718A1 (fr) * 2006-12-19 2008-06-26 Riken Molécule fluorescente
US8426127B2 (en) 2006-12-19 2013-04-23 Riken Fluorescence-producing molecule

Also Published As

Publication number Publication date
AU5209199A (en) 2000-02-01
US6696241B2 (en) 2004-02-24
US20010049091A1 (en) 2001-12-06
WO2000003033A9 (fr) 2000-10-05

Similar Documents

Publication Publication Date Title
Bhati et al. Molecular characterization of human breast tumor vascular cells
US20140323342A1 (en) Methods and Compositions for the Treatment and Diagnosis of Bladder Cancer
JP2020073924A (ja) がん免疫療法の臨床効果を予測する免疫学的バイオマーカー
US20140206574A1 (en) Methods and Compositons for the Treatment and Diagnosis of Cancer
CA2844822A1 (fr) Methodes et compositions pour le traitement et le diagnostic du cancer colorectal
WO2013025952A2 (fr) Procédés et compositions pour le traitement et le diagnostic du cancer du sein
US20150018235A1 (en) Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
US20210148916A1 (en) Methods for Monitoring Polymorphonuclear Myeloid Derived Suppressor Cells and Compositions and Methods of Treatment of Cancer
WO2012178087A1 (fr) Méthodes et compositions pour traitement et diagnostique d'un cancer de la vessie
US20150335679A1 (en) Methods and Compositions for Treating Malignancies with Dendritic Cells
US6696241B2 (en) Measuring esterase activity using fluorescent substrates as a way of evaluating cervical cancer
Squire et al. The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma
KR102197723B1 (ko) 림프구의 종양 반응성 예측용 마커 및 이의 용도
US20140088169A1 (en) Genetic changes in atm and atr/chek1 as prognostic indicators in cancer
Johnson et al. Clinical manufacture of CRISPR/Cas9-based cytokine-induced SH2 protein knock-out tumor-infiltrating lymphocytes for gastrointestinal cancers
TW202001245A (zh) 藉由去糖基化偵測免疫檢查點分子
JP2002505433A (ja) 単一細胞におけるｐＲＢのコンホメーションのフローサイトメトリによる検出
EP2138844A1 (fr) Procédé pour tester la réponse de cellules aux expositions des thérapies
Yang et al. Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues
EP1959022B1 (fr) Detection d un leiomyosarcome uterin au moyen de lmp2
Winikoff et al. Cytolytic assays
US11693007B2 (en) Assay for detection of early stage pancreatic cancer
CN111868265B (zh) Dna重组修复功能评分rds在癌症治疗中的用途
Xiao Investigation of the impact of HNPCC gene deficiency on outcome in epithelial ovarian cancer
PROLIFERATIVE Prize Posters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 09755880

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase